<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919489</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00068128</org_study_id>
    <secondary_id>(UTN) U1111-1139-2991</secondary_id>
    <nct_id>NCT01919489</nct_id>
  </id_info>
  <brief_title>Liraglutide Hospital Discharge Trial</brief_title>
  <official_title>A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with
      increased risk of medical complications and death. Improved glucose control with insulin
      injections may improve clinical outcome and prevent some of the hospital complications.
      Increasing evidence indicates that incretin-based agents are safe and effective for the
      hospital management of patients with type 2 diabetes (T2D).

      Liraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the
      treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous
      insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food
      intake and body weight and improve ß-cell function when administered subcutaneously.
      Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when plasma
      glucose levels are elevated), resulting in low-risk of hypoglycemia when used as monotherapy.
      When compared to insulin glargine therapy, the use of GLP-1 has resulted in comparable
      reduction in HbA1c level, lower rates of hypoglycemia and less weight gain. No prospective
      studies; however, have compared the efficacy and safety of liraglutide in the hospital
      setting or after hospital discharge.

      The primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus
      glargine insulin in combination to oral anti-diabetic agents (OADs: metformin, sulfonylureas,
      nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks of treatment in
      medicine patients with T2D after hospital discharge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in
      similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events compared
      to treatment with glargine (Lantus®) in patients with T2D after hospital discharge. Patients
      with poorly controlled (HbA1c &gt;7%-10%) T2D treated with diet or oral antidiabetic agents or
      low dose insulin naïve (0.4u/kg/day) prior to admission will be randomized to liraglutide or
      glargine in combination to OADs at hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>After discharge, 6 months</time_frame>
    <description>To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting and postprandial blood glucose (BG) concentration</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>To determine differences in BG concentration between liraglutide and glargine insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Number of hypoglycemic events (&lt;70 mg/dl) and severe hypoglycemic events (&lt;40 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no hypoglycemia</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no weight gain</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no hypoglycemia</measure>
    <time_frame>After discharge, average 12 weeks</time_frame>
    <description>Percent of patients with 12 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight and BMI</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Change in body weight and BMI after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of insulin</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Evaluate the total daily dose of insulin needed in the group receiving glargine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Cardiovascular risk factors including changes in blood pressure, heart rate, and lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency room visits and readmissions</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Number of emergency room visits and hospital readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <description>Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine &gt; 0.5 mg/dL from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide + OADs</intervention_name>
    <description>Liraglutide subcutaneously daily</description>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <other_name>Victoza® + OADs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine + OADs</intervention_name>
    <description>Glargine once daily subcutaneously</description>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <other_name>Glargine (Lantus®) + OADs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years discharged after hospital
             admission from general surgery and medicine services (non-surgical and non-ICU
             setting).

          2. Admission HbA1c between 7% and 10%

          3. Patients with T2D treated with diet alone or with oral antidiabetic agents as
             monotherapy or in combination therapy (excluding GLP1 receptor agonists) or on
             low-dose insulin therapy (TDD ≤0.4 unit/kg/day) prior to admission.

          4. Subjects with a hospital admission BG &lt; 400 mg/dL without laboratory evidence of
             diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or positive serum or urinary
             ketones).

          5. BMI &gt; 25 Kg/m2 and &lt; 45 Kg/m2

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with increased BG concentration, but without a history of diabetes (stress
             hyperglycemia)

          3. Subjects with a history of type 1 diabetes (suggested by BMI &lt; 25 Kg/m2 requiring
             insulin therapy or with a history of diabetic ketoacidosis and hyperosmolar
             hyperglycemic state, or ketonuria).

          4. Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.

          5. Recurrent severe hypoglycemia or hypoglycemic unawareness.

          6. Subjects with gastrointestinal obstruction, gastroparesis or those expected to require
             gastrointestinal suction.

          7. History of medullary thyroid cancer or multiple endocrine neoplasia

          8. Patients with acute or chronic pancreatitis, pancreatic cancer or gallbladder disease.

          9. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage
             liver disease, portal hypertension) and elevated ALT and AST &gt; 3 times upper limit of
             normal, or significantly impaired renal function (GFR &lt; 30 ml/min).

         10. Treatment with oral or injectable corticosteroid, parenteral nutrition and
             immunosuppressive treatment.

         11. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         12. Female subjects who are pregnant or breast feeding at time of enrollment into the
             study.

         13. Females of childbearing potential who are not using adequate contraceptive methods (as
             required by local law or practice).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <phone>404-778-1665</phone>
    <email>geumpie@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco J Pasquel, MD</last_name>
    <phone>404 778 1697</phone>
    <email>fpasque@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Iacobellis, MD</last_name>
      <email>GIacobellis@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Gianluca Iacobellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo E Umpierrez, MD</last_name>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francisco J Pasquel, MD</last_name>
      <phone>404 778 1697</phone>
      <email>fpasque@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Guillermo Umpierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Pasquel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priya Vellanki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Pasquel, MD</last_name>
      <email>fpasque@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Francisco Pasquel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Universtiy Hospital at MIdtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Pasquel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rodolfo J Galindo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State University of NY at Buffalo</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajay Chaudhuri, MD</last_name>
      <email>AChaudhuri@KaleidaHealth.Org</email>
    </contact>
    <investigator>
      <last_name>Ajay Chaudhuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Incretins</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Glargine</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>basal insulin</keyword>
  <keyword>hospital discharge</keyword>
  <keyword>inpatient diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

